DKSH has signed an agreement to acquire MDxK, a South Korean provider of advanced scientific solutions. MDxK specializes in molecular diagnostics, cellular analysis, structural biology, and biobanking. The acquisition enhances DKSH’s position in the molecular diagnostics market, strengthens its scientific workflow solutions, and solidifies its presence in South Korea’s life science sector.
MDxK: A Trusted Leader in Scientific Solutions
MDxK has built strong relationships with renowned global life science clients. The company focuses on molecular diagnostics and research, serving hospitals, research institutes, laboratories, universities, pharmaceutical companies, and food & beverage firms. MDxK employs approximately 25 professionals and generates annual net sales of around CHF 10 million with solid profitability.
Strategic Growth and Market Expansion
Hanno Elbraechter, Head of DKSH’s Business Unit Technology, stated, “MDxK is a well-established scientific solutions provider that perfectly complements our portfolio. With increasing healthcare demands and a growing focus on research and development, we expect significant market growth in South Korea. We are excited to build on MDxK’s existing success and leverage synergies created through this acquisition.”
Leadership Transition and Future Prospects
Sungbo Shim, Owner and Managing Director of MDxK, remarked, “This acquisition marks an important milestone in our nearly 20-year journey and aligns with our leadership transition strategy. We are confident that DKSH’s strong sales channels and market reach will benefit our business partners and employees. We look forward to expanding our business under DKSH’s leadership.”
Expected Transaction Closure
As reported by markets.businessinsider.com, DKSH anticipates closing the transaction in the second quarter of 2025, pending regulatory approvals and other conditions.
